With the development of EGFR-TKIs, advanced NSCLC patients with sensitive EGFR mutations have many choices, including gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, furmonertinib, and befotertinib, which restricts the number of people receiving a specific drug. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.